Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated:  11/17/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated: 11/17/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated:  11/17/2017
University of Michigan
mi
from
Ann Arbor, MI
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated: 11/17/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated:  11/17/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated: 11/17/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated:  11/17/2017
Oregon Health and Science University
mi
from
Portland, OR
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated: 11/17/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated:  11/17/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated: 11/17/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated:  11/17/2017
Vanderbilt University
mi
from
Nashville, TN
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated: 11/17/2017
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated:  11/17/2017
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated: 11/17/2017
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated:  11/17/2017
All Children's Research Institute
mi
from
Saint Petersburg, FL
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated: 11/17/2017
All Children's Research Institute
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated:  11/17/2017
Washington University
mi
from
Saint Louis, MO
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated: 11/17/2017
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated:  11/17/2017
Childrens National Medical Center
mi
from
Washington,
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Status: Enrolling
Updated: 11/17/2017
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
University of Chicago, School of Medicine
mi
from
Chicago, IL
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
University of Chicago, School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
University of Maryland
mi
from
Baltimore, MD
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
University of Michigan
mi
from
Ann Arbor, MI
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
University of Chicago Medical Center
mi
from
Chicago, IL
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
University of Maryland
mi
from
Baltimore, MD
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
Karmanos Cancer Center
mi
from
Detroit, MI
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
Peter MacCallum Cancer Centre
mi
from
East Melbourne,
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
Peter MacCallum Cancer Centre
mi
from
East Melbourne,
Click here to add this to my saved trials
Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Prospective Observational Study Measuring the Short-Form36 ( SF-36v2) and Other QOL Tools in an AL Amyloidosis Population
Status: Enrolling
Updated:  11/20/2017
Online registry
mi
from
South San Francisco, CA
Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Prospective Observational Study Measuring the Short-Form36 ( SF-36v2) and Other QOL Tools in an AL Amyloidosis Population
Status: Enrolling
Updated: 11/20/2017
Online registry
mi
from
South San Francisco, CA
Click here to add this to my saved trials
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  11/21/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 11/21/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease
A Pilot Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  11/22/2017
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease
A Pilot Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 11/22/2017
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
A Pilot Study Assessing the Use of Continuous Subcutaneous Hydrocortisone Infusion in the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated:  11/24/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
A Pilot Study Assessing the Use of Continuous Subcutaneous Hydrocortisone Infusion in the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated: 11/24/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Stanford University Medical Center, Division of Hematology
mi
from
Stanford, CA
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Stanford University Medical Center, Division of Hematology
mi
from
Stanford, CA
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst.
mi
from
Atlanta, GA
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst.
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Georgia Regents University MedCollege of GA Cancer Ctr 2
mi
from
Augusta, GA
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Georgia Regents University MedCollege of GA Cancer Ctr 2
mi
from
Augusta, GA
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Hematology/Oncology of the North Shore Orchard Healthcare Res. Inc.
mi
from
Skokie, IL
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Hematology/Oncology of the North Shore Orchard Healthcare Res. Inc.
mi
from
Skokie, IL
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2)
mi
from
Somerset, NJ
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2)
mi
from
Somerset, NJ
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Montefiore Medical Center
mi
from
Bronx, NY
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Duke University Medical Center Dept. of DUMC (4)
mi
from
Durham, NC
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Duke University Medical Center Dept. of DUMC (4)
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt UMC
mi
from
Nashville, TN
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt UMC
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
MD Anderson Cancer Center/University of Texas MD Anderson CC
mi
from
Houston, TX
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
MD Anderson Cancer Center/University of Texas MD Anderson CC
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
A Phase 2 Study of Lenalidomide and Low-dose Dexamethasone in Combination With Dalteparin in Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
A Phase 2 Study of Lenalidomide and Low-dose Dexamethasone in Combination With Dalteparin in Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia
Autologous Marrow Transplantation for Chronic Myelogenous Leukemia Using Stem Cells Obtained After In Vivo Cyclophosphamide/G-CSF Priming
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia
Autologous Marrow Transplantation for Chronic Myelogenous Leukemia Using Stem Cells Obtained After In Vivo Cyclophosphamide/G-CSF Priming
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia
Autologous Transplantation for Chronic Myelogenous Leukemia Using Retrovirally Marked Peripheral Blood Progenitor Cells Obtained After In Vivo Cyclophosphamide/G-CSF Priming
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia
Autologous Transplantation for Chronic Myelogenous Leukemia Using Retrovirally Marked Peripheral Blood Progenitor Cells Obtained After In Vivo Cyclophosphamide/G-CSF Priming
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
Autologous Transplantation for Multiple Myeloma: A Research Study of Multiple Myeloma Using Chemotherapy Plus Growth Factor Primed Peripheral Blood Stem Cells Followed by Autologous Transplantation and Post-Transplant Immunotherapy
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
Autologous Transplantation for Multiple Myeloma: A Research Study of Multiple Myeloma Using Chemotherapy Plus Growth Factor Primed Peripheral Blood Stem Cells Followed by Autologous Transplantation and Post-Transplant Immunotherapy
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bone Marrow Transplantation in Treating Patients With Leukemia
T-cell Depletion In Unrelated Donor Marrow Transplantation
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Bone Marrow Transplantation in Treating Patients With Leukemia
T-cell Depletion In Unrelated Donor Marrow Transplantation
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia
Treatment of Relapsed Leukemia After Allogeneic Bone Marrow Transplantation Using Donor-derived Lymphocytes
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia
Treatment of Relapsed Leukemia After Allogeneic Bone Marrow Transplantation Using Donor-derived Lymphocytes
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Transplantation of Umbilical Cord Blood From Related and Unrelated Donors
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Transplantation of Umbilical Cord Blood From Related and Unrelated Donors
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
A Cyclophosphamide/Fludarabine/Total Body Irradiation Preparative Regimen for Patients With Hematological Malignancy Receiving Unrelated Donor Umbilical Cord Blood Transplantation
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
A Cyclophosphamide/Fludarabine/Total Body Irradiation Preparative Regimen for Patients With Hematological Malignancy Receiving Unrelated Donor Umbilical Cord Blood Transplantation
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
CPG 7909 Oligodeoxynucleotides (ODNS) After Autologous Transplantation to Enhance Immune Reconstitution
Status: Enrolling
Updated:  11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
CPG 7909 Oligodeoxynucleotides (ODNS) After Autologous Transplantation to Enhance Immune Reconstitution
Status: Enrolling
Updated: 11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase I-II Dose Escalation Study of CD4+CD25+ Cells in Adult Patients Undergoing HLA-Identical Sibling Donor Peripheral Blood Progenitor Cell Transplantation
Status: Enrolling
Updated:  11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase I-II Dose Escalation Study of CD4+CD25+ Cells in Adult Patients Undergoing HLA-Identical Sibling Donor Peripheral Blood Progenitor Cell Transplantation
Status: Enrolling
Updated: 11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
A Phase I/II Randomized, Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Use of Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
Status: Enrolling
Updated:  11/27/2017
Illinois Eye and Ear Infirmary, University of Illinois
mi
from
Chicago, IL
Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
A Phase I/II Randomized, Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Use of Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
Status: Enrolling
Updated: 11/27/2017
Illinois Eye and Ear Infirmary, University of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
A Phase I/II Randomized, Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Use of Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
Status: Enrolling
Updated:  11/27/2017
Translational Clinic of Corneal Neurobiology Laboratory, Illinois Eye and Ear Infirmary, University of Illinois
mi
from
Chicago, IL
Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
A Phase I/II Randomized, Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Use of Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
Status: Enrolling
Updated: 11/27/2017
Translational Clinic of Corneal Neurobiology Laboratory, Illinois Eye and Ear Infirmary, University of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials